secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-040973
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics Q2 net loss $20.2M, cash $181M; Phase 3 atacicept trial initiated
--------------------------------------------------------------------------------

- Net loss of $20.2M ($0.46 per share) vs $14.9M ($0.55 per share) in Q2 2022.
- Cash, cash equivalents, and marketable securities of $181.0M as of June 30, 2023; funds operations to early 2026.
- Positive 36-week Phase 2b ORIGIN results: significant proteinuria reduction and eGFR stabilization.
- Pivotal Phase 3 ORIGIN 3 trial for IgA nephropathy initiated in June 2023.
- Preliminary ORIGIN 3 data expected in first half of 2025; additional Phase 2b data in H2 2023 and 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000095017023040973/0000950170-23-040973-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000095017023040973/vera-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-040973

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer